February 2025 - BioMedWire (BMW)

FridayFeb 28, 2025 11:00 am

Clene Inc. (NASDAQ: CLNN) Leverages APST’s NfL Database to Support FDA-Recommended Analyses for ALS Drug

Clene is partnering with APST Research GmbH to analyze neurofilament light chain (“NfL”) data for evaluating CNM-Au8® in ALS patients. APST maintains one of the largest ALS biomarker databases, with data from over 4,300 ALS patients, including clinical outcomes and biomarker tracking. The analysis will compare NfL changes in the NIH-sponsored Expanded Access Program (“EAP”) participants with historical ALS patient data to assess CNM-Au8’s potential efficacy. Clene plans to submit its statistical analysis plan to the FDA, aiming for filing of an NDA for potential accelerated approval in the second half of 2025. No significant safety concerns have been reported…

FridayFeb 28, 2025 10:00 am

Layoffs, Upheaval at CDC Trigger Fears on Handling Disease Outbreaks

America is facing threats of infectious diseases on multiple fronts; cases of measles are escalating in Texas and the surrounding states, bird flu is spreading across the country, and cases of polio and Ebola abroad pose an added risk to Americans due to international travel. Amid all these threats of infectious diseases, the U.S. CDC is experiencing mass layoffs and a great deal of uncertainty triggered by Trump’s efforts to downsize federal health agencies and reduce government spending. The firings have put a strain on personnel numbers within the CDC and it is getting harder to respond appropriately to any…

ThursdayFeb 27, 2025 10:45 am

Adageis Drives Value-Based Care Transition as Healthcare Switches from Artificial General Intelligence to Specific Use Cases

Healthcare providers are increasingly prioritizing specific, high-impact AI applications that enhance patient care and financial performance. Adageis' ProActive Care Platform leverages AI to enhance risk assessment, workflow optimization, and revenue tracking for providers. AI-driven patient monitoring and early intervention reduce hospital readmissions and improve care quality. Adageis’ Patented Risk Engine helps healthcare providers proactively address high-risk patients, improving outcomes while increasing reimbursements. Seamless integration with multiple EHR systems ensures easy adoption without disrupting provider workflows. As in other areas, artificial intelligence is making a measurable impact on healthcare, but the focus is shifting. While artificial general intelligence (“AGI”) once dominated…

ThursdayFeb 27, 2025 10:00 am

Kids with Autism are Less Prone to Severe Injuries Compared to Those with ADHD

New research that appeared in JAMA Network Open discovered that kids with autism have a reduced likelihood of suffering injuries when compared to kids diagnosed with ADHD (attention-deficit/hyperactivity disorder). This study provides insights that could help in working out how to manage injuries in these different groups of children. Researchers from Clalit Health Services, Ben-Gurion University, and Loewenstein Rehabilitation Medical Center obtained data on 325,412 kids born from 2005 to 2009 within Israel. They then analyzed this data with a special focus on the rates of injury for kids with autism alone, those with ADHD only, as well as those…

TuesdayFeb 25, 2025 11:30 am

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Drives Growth with Strengthened Financial Position and Cutting-Edge Research

One of the most significant challenges facing biotechnology companies is securing adequate funding to sustain research and development efforts. Calidi’s improved financial footing reassures investors and allows the company to focus on achieving key milestones in its research pipeline. The company has been selected to present new data on its RTNova systemic virotherapy platform at the prestigious AACR annual meeting in April 2025. Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company, is making significant strides in the field of cancer immunotherapy. Known for its innovative approach to antitumor virotherapies, Calidi is focused on harnessing the power of its patented…

TuesdayFeb 25, 2025 10:45 am

How Adageis Simplifies Value-Based Care, Boosting Revenue for Healthcare Providers

Adageis streamlines complex insurance contracts, helping providers maximize reimbursements. The company’s AI-driven solutions reduce administrative burden, freeing up time for patient care. Seamless integration with nearly 100 EHR systems ensures a smooth transition to value-based care models. The company’s fintech approach enhances financial performance, with providers seeing up to $75,000 in additional revenue. Adageis projects significant growth, expecting to cover 580,000 patient lives by mid-2025. Healthcare is shifting toward value-based care, where providers are reimbursed for patient outcomes rather than the number of procedures performed. While the model promises higher-quality care at lower costs, it also introduces complex reimbursement structures…

TuesdayFeb 25, 2025 10:00 am

2025 eCommerce Trends That Could Be Game Changers for Your Online Business

The worldwide e-commerce market is predicted to expand by 7.8% and reach a market value of $6.5 trillion by the end of this year. As an e-commerce operator, it is in your best interest to leverage the emerging trends so that your business can claim its fair share of this expanding market. We discuss some of those trends below. Social Commerce This is one big trend to watch if you are into e-commerce. Social media as well as other digital channels are the hallmarks in this trend. The concept allows transactions to happen easily between businesses and their target clientele.…

MondayFeb 24, 2025 1:00 pm

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Sees Growth, Potential in Oncology Drug Development, a Critical Frontier in Cancer Treatment

According to the American Cancer Society, cancer is the second leading cause of death globally. Oncology drugs are a cornerstone of modern cancer treatment. Calidi Biotherapeutics is a cutting-edge biotechnology company dedicated to developing innovative cancer treatments. Cancer continues to be one of the most significant health challenges of our time, with its global impact growing every year. The increasing number of cancer diagnoses and related deaths underscores the urgent need for more effective treatments, including advanced oncology drugs. Companies such as Calidi Biotherapeutics (NYSE American: CLDI) are at the forefront of research and development, offering hope for millions of patients worldwide.…

FridayFeb 21, 2025 11:30 am

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Focuses Innovation on Hard-to-Treat Tumors

As cancer numbers grow, Calidi Biotherapeutics is at the forefront of developing novel treatments aimed at improving patient outcomes. Calidi’s platform centers on the use of antitumor virotherapies that selectively infect and kill cancer cells while activating the body’s own immune system to attack the tumor. The company’s therapeutic pipeline targets multiple cancer indications, with a focus on hard-to-treat tumors. Cancer remains a significant global health challenge, with certain types exhibiting particularly high mortality rates. Glioblastoma multiforme (“GBM”), triple-negative breast cancer (“TNBC”), sarcoma and lung cancer are among the most aggressive and deadly forms, necessitating urgent advancements in research and…

FridayFeb 21, 2025 10:00 am

Europe is Facing a Growing Shortfall of General Practitioners

Data shows that Europe is facing a growing deficit of doctors across all specialties, and the declining number of general practitioners stands out strongly. Current GPs aren’t evenly distributed and the fact that they are aging and leaving active service makes the problem worse. Traditionally, GPs have served as the first point of contact when someone is facing a health challenge. These professionals handle most patients and refer those who need additional care to specialists. This primary healthcare role has earned them the tag ‘family doctor.’ However, countries across Europe are faced with a double whammy; their general populations are…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Month: February 2025

Clene Inc. (NASDAQ: CLNN) Leverages APST’s NfL Database to Support FDA-Recommended Analyses for ALS Drug

Layoffs, Upheaval at CDC Trigger Fears on Handling Disease Outbreaks

Adageis Drives Value-Based Care Transition as Healthcare Switches from Artificial General Intelligence to Specific Use Cases

Kids with Autism are Less Prone to Severe Injuries Compared to Those with ADHD

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Drives Growth with Strengthened Financial Position and Cutting-Edge Research

How Adageis Simplifies Value-Based Care, Boosting Revenue for Healthcare Providers

2025 eCommerce Trends That Could Be Game Changers for Your Online Business

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Sees Growth, Potential in Oncology Drug Development, a Critical Frontier in Cancer Treatment

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Focuses Innovation on Hard-to-Treat Tumors

Europe is Facing a Growing Shortfall of General Practitioners

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search